Skip to main content
SpringerLink
Log in

NICE wants more info on teriflunomide for MS

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. Draft guidance from NICE asks for more information on multiple sclerosis treatment. Media Release : 18 Sep 2013. Available from: URL: http://www.nice.org.uk.

  2. NICE. NICE proposes green light to treatment for common eye problem in people with diabetes in final draft guidance. Media Release : 1 Oct 2013. Available from: URL: http://www.nice.org.uk.

  3. NICE. NICE guidance recommends new test to guide breast cancer treatment decisions. Media Release : 24 Sep 2013. Available from: URL: http://www.nice.org.uk.

  4. NICE. NICE publishes draft guidance on suite of ovarian cancer drugs. Media Release : 26 Sep 2013. Available from: URL: http://www.nice.org.uk.

  5. NICE. Pfizer's crizotinib not good value for NHS money, says NICE. Media Release : 25 Sep 2013. Available from: URL: http://www.nice.org.uk.

Download references

Additional information

* incremental cost-effectiveness ratio

Rights and permissions

Reprints and permissions

About this article

Cite this article

NICE wants more info on teriflunomide for MS. PharmacoEcon Outcomes News 688, 11 (2013). https://doi.org/10.1007/s40274-013-0772-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0772-0

Search

Navigation